Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Telo Genomics Corp
(OP:
TDSGF
)
0.0954
+0.0034 (+3.70%)
Streaming Delayed Price
Updated: 11:19 AM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
240
Open
0.0954
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0920
Today's Range
0.0954 - 0.0954
52wk Range
0.0795 - 0.2372
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
EXCLUSIVE: Telo Genomics' Smoldering Multiple Myeloma Prognostic Test Predicts Risk Of Disease Progression, Study Shows
May 30, 2024
American Journal of Hematology accepts Telo Genomics' study on TeloViewSMM, a prognostic test for smoldering multiple myeloma. The test showed 85% positive and 73% negative predictive values, offering...
Via
Benzinga
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
Performance
YTD
-50.23%
-50.23%
1 Month
-27.45%
-27.45%
3 Month
-7.83%
-7.83%
6 Month
-23.50%
-23.50%
1 Year
-47.73%
-47.73%
More News
Read More
Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation
October 26, 2023
Via
Newsfile
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
October 17, 2023
Via
FinancialNewsMedia
Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM – An Important Commercial Milestone Achieved
October 17, 2023
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting
October 12, 2023
Via
FinancialNewsMedia
Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study
September 14, 2022
Via
Newsfile
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.